Affimed (AFMD) Receiving Somewhat Positive Media Coverage, Study Shows
News coverage about Affimed (NASDAQ:AFMD) has trended somewhat positive on Friday, according to Accern Sentiment. The research group ranks the sentiment of news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Affimed earned a media sentiment score of 0.15 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 45.9092414289545 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Shares of Affimed (NASDAQ AFMD) traded up $0.07 during trading on Friday, hitting $1.30. 573,100 shares of the company traded hands, compared to its average volume of 297,115. The company has a quick ratio of 6.39, a current ratio of 6.43 and a debt-to-equity ratio of 0.14. Affimed has a 52-week low of $1.15 and a 52-week high of $2.95.
A number of analysts have recently weighed in on the stock. Oppenheimer restated a “hold” rating on shares of Affimed in a report on Friday, November 24th. ValuEngine cut shares of Affimed from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st.
Affimed Company Profile
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.